Azerra (ofatumumab) is a new antibiody against Chronic lymphocytic leukemia( CLL). Preclinical data suggest that it might be more effective than Rituxan in variety of lymphomas. In early clinical trials, ofatumumab demonstrated single-agent activity against chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin’s lymphomas. It was approved by the US Food and Drug Administration for the treatment of CLL that is resistant to both fludarabine and alemtuzumab. In In early clinical trials, ofatumumab demonstrated single-agent activity against CLL and a number of subtypes of B-cell non-Hodgkin’s lymphomas.
Not much is known about using this drug for mantle cell lymphoma. Preclinical comparisons make it appears superior to rituxumab but there are also studies in which it does not. A recent review noted that pre-clinical data suggest improved cell killing for ofatumumab compared with rituximab. Ofatumumab is in a clinical trial for Mantle cell lymphoma: Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell TransplantThis study is being done to understand how to treat Mantle Cell Lymphoma (MCL).
M. Magni presented an abstract in the 2011 ASH conference. It reported that chemotherapy with bendamustine and ofatumumab appears generally safe and well tolerated to date in MCL patients aged ≥ 65 years requiring treatment. Preliminary data about efficacy are encouraging: accrual is ongoing for further evaluation.
For Professional version see here